Financial Performance - Consolidated revenue decreased by 3.7% year-over-year, from $22.245 billion in 3Q24 to $21.415 billion in 3Q25[23] - Non-GAAP adjusted operating profit increased by 7.5% year-over-year, from $1.983 billion in 3Q24 to $2.132 billion in 3Q25[23] - Non-GAAP adjusted operating margin increased by 110 basis points year-over-year, from 8.9% in 3Q24 to 10.0% in 3Q25[23] - Non-GAAP adjusted diluted EPS decreased by 1.1% year-over-year, from $1.76 in 3Q24 to $1.74 in 3Q25[23] - The company expects to end the year with approximately $5.0 billion in cash following the completion of the Andlauer Healthcare Group acquisition[52] Segment Performance - U S Domestic revenue decreased by 2.6% year-over-year, with revenue of $14.2 billion in 3Q25 compared to $14.6 billion in 3Q24[38, 39] - U S Domestic revenue per piece (RPP) improved by 9.8% year-over-year[23, 40] - International revenue increased by 5.9% year-over-year, from $4.4 billion in 3Q24 to $4.7 billion in 3Q25[45] - Supply Chain Solutions revenue decreased by 22.1% year-over-year, from $3.2 billion in 3Q24 to $2.5 billion in 3Q25, with $465 million of the decrease due to the divestiture of Coyote in 3Q24[46] - Supply Chain Solutions non-GAAP adjusted operating profit increased by 97.1% year-over-year, from $272 million in 3Q24 to $536 million in 3Q25, including a $330 million gain from a sale-leaseback transaction[46, 15] Operational Updates and Outlook - Amazon's total volume was down 21.2% year-over-year in 3Q25[27, 51] - The company is on track to achieve its 2025 expense reduction target of approximately $3.5 billion related to the Amazon volume glide-down[49, 50] - The company anticipates consolidated revenue of approximately $24.0 billion and a non-GAAP adjusted operating margin of approximately 11.0%-11.5% for 4Q25[31, 54]

Regeneron Corporate Presentation O C T O B E R 2 0 2 5 This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may ...

Financial Performance - Q3 2025 sales reached $1.1 billion, a 7% year-over-year increase[7] - Adjusted EBITDA for Q3 2025 was $225 million, up 21% year-over-year, including ~$10 million gains from oil & gas rights sale[7] - Adjusted EBITDA margin for Q3 2025 was 20%, a 230 bps increase year-over-year[7] - Adjusted EPS for Q3 2025 was $0.85, a 42% year-over-year increase[7] Segment Performance - Aerospace & Defense (A&D) accounted for 70% of total sales, with $793 million in Q3[3, 13] - HPMC (High Performance Materials & Components) sales were $603 million, up 9% year-over-year, with an adjusted EBITDA margin of 24%, a 190 bps increase[15] - AA&S (Advanced Alloys & Solutions) sales were $523 million, up 5% year-over-year, with an adjusted EBITDA margin of 17%, a 250 bps increase[20] Growth Drivers - Significant defense growth with a 51% year-over-year increase in Q3[13] - Strong jet engine growth with a 19% year-over-year increase[13] - Airframe growth driven by share gains, up 9% year-over-year[13] Capital Allocation - $150 million in share repurchases were made in Q3, with ~$1 billion repurchased since 2022 at an average price of ~$51 per share[9] - Liquidity of ~$1 billion, including $372 million of cash on hand[34] Outlook - Full-year Adjusted EBITDA guidance raised to $848 - $858 million[9, 35] - Full-year Adjusted EPS guidance raised to $3.15 - $3.21[9, 35]

Third-Quarter 2025 Investor Call Corning Reports Third-Quarter 2025 Financial Results October 28, 2025 Forward-Looking and Cautionary Statements The statements contained in this presentation and related comments by management that are not historical facts or information and contain words such as "will," "believe," "anticipate," "expect," "intend," "plan," "seek," "see," "would," "target," "estimate," "forecast" or similar expressions are forward-looking statements. These forward-looking statements are made ...

Q3 2025 Financial Performance - Total property revenue increased by 5.9% year-over-year to $2616 million, or 4.2% on an FX-Neutral basis[5] - Total revenue increased by 7.7% year-over-year to $2717 million, or 6.1% on an FX-Neutral basis[5] - Net income attributable to AMT common stockholders was $853 million, a 207.7% increase compared to a loss of $792 million in Q3 2024[5] - Adjusted EBITDA increased by 7.6% year-over-year to $1816 million, or 6.2% on an FX-Neutral basis[5] - AFFO attributable to AMT common stockholders increased by 5.3% year-over-year to $1303 million, or 3.9% on an FX-Neutral basis[5] - AFFO attributable to AMT common stockholders, as adjusted, increased by 10.4% year-over-year to $1303 million, or 8.8% on an FX-Neutral basis[5] Updated 2025 Outlook - The company is raising its property revenue outlook midpoint by $40 million to $10250 million, primarily due to FX tailwinds[21] - The company is raising its Adjusted EBITDA outlook midpoint by $45 million to $7085 million, primarily due to FX tailwinds and U S Services outperformance[25] - The company is raising its Attributable AFFO outlook midpoint by $50 million to $5000 million, primarily due to FX tailwinds, conversion of topline growth and net interest benefits[28] Capital Allocation - The company is targeting a common dividend declaration of approximately $32 billion[32, 35] - Discretionary capital projects are allocated as follows: U S Data Centers ~40%, U S & Canada ~25%, Europe ~15%, and Emerging Markets ~20%[32]

Financial Performance - Zebra Technologies reported net sales of $1,320 million, a 5.2% increase compared to $1,255 million in 3Q24 [14] - Organic net sales growth was 4.8% [10, 14] - Adjusted EBITDA margin increased by 20bps to 21.6% [10, 14] - Non-GAAP diluted EPS increased by 11.2% to $3.88 [10, 14] Segment and Regional Performance - Asset Intelligence & Tracking segment organic net sales grew by 10.6% [15] - Enterprise Visibility & Mobility segment organic net sales grew by 2.0% [15] - Asia Pacific region organic net sales grew by 23% [15] - Latin America region organic net sales grew by 8% [15] - North America region organic net sales grew by 6% [15] - EMEA region organic net sales declined by 3% [15] Cash Flow and Balance Sheet - Free cash flow was $504 million year-to-date [17] - The company closed the Elo Touch Solutions acquisition for $1.3 billion [17] - The company has $1,053 million in cash and cash equivalents [17] - The company expects to substantially mitigate U S import tariffs entering 2026 [18]

Financial Performance - Q3 2025 - Sales were $1.036 billion, a 6% decrease year-over-year[7,8] - Volume decreased by 6%[7] - Adjusted EBIT was $73 million, down 4% year-over-year, with an adjusted EBIT margin of 7.0%, up 10 bps year-over-year[7,8] - Adjusted EPS was $0.29, down $0.03 year-over-year[7] - Operating cash flow was $126 million, up 32% year-over-year[7,8] Financial Performance - YTD 2025 - Sales were $3.117 billion, a 6% decrease year-over-year[15] - Adjusted EBIT was $215 million, up 2% year-over-year, with an adjusted EBIT margin of 6.9%, up 60 bps year-over-year[15] - Adjusted EPS was $0.83, down 1% year-over-year[15] - Operating cash flow was $217 million, up 18% year-over-year[15] Guidance - The company reaffirmed its 2025 sales guidance of $4.0–$4.1 billion, representing a 6% to 9% decrease versus 2024[7,19] - The company reaffirmed its adjusted EPS guidance of $1.00–$1.10[7,19]

Financial Performance - Total company revenues increased by 1% to $3,519 million in 3Q 2025 compared to $3,480 million in 3Q 2024[8] - Rental days for the total company increased by 1% to 49,400 thousand in 3Q 2025 compared to 48,786 thousand in 3Q 2024[8] - Adjusted EBITDA for the total company increased by 11% to $559 million in 3Q 2025 compared to $503 million in 3Q 2024[8] - Americas revenues decreased by 1% to $2,621 million in 3Q 2025 compared to $2,640 million in 3Q 2024, but U S rental car revenue increased by 1%[9] - International revenues increased by 2% to $859 million in 3Q 2025 compared to $840 million in 3Q 2024, excluding exchange rate effects[10] Key Metrics - Revenue per day excluding exchange rate effects for the total company decreased by 1% to $7049 in 3Q 2025 compared to $7132 in 3Q 2024[8] - Per-unit fleet costs per month excluding exchange rate effects for the total company decreased by 18% to $299 in 3Q 2025 compared to $365 in 3Q 2024[8] - Vehicle utilization for the total company decreased slightly by 01 percentage points to 720% in 3Q 2025 compared to 721% in 3Q 2024[8] Liquidity and Outlook - Adjusted Free Cash Flow year-to-date was negative $517 million, impacted by over $1 billion in voluntary fleet contributions[11] - The company anticipates Adjusted EBITDA for FY 2025 to be at the low end of the previously stated $900 million - $1,000 million range[17] - Per-unit fleet costs per month for FY 2025 are expected to be approximately $310-$320, and around $300 in 4Q 2025[17, 18]

Scaling for Sustainable Growth Q3 2025 EARNINGS CONFERENCE CALL October 28, 2025 Herc Rentals Team and Agenda President & Chief Executive Officer Q&A Larry Silber Aaron Birnbaum Senior Vice President & Chief Operating Officer Mark Humphrey Senior Vice President & Chief Financial Officer Leslie Hunziker Senior Vice President Investor Relations, Communications & Sustainability Agenda Safe Harbor Q3 2025 Overview Q3 Operations Review Q3 Financial Review 2025 Outlook Herc Holdings Inc. NYSE: HRI Q3 2025 2 Safe ...

Financial Performance - ARCALYST Q3 2025 revenue reached $180.9 million, representing approximately 61% year-over-year growth[10] - The company raised full-year 2025 net revenue guidance to between $670 million and $675 million, up from the previous guidance of between $625 million and $640 million[10] - Total prescribers of ARCALYST exceeded 3,825 as of Q3 2025[20] - Repeat prescribers of ARCALYST were approximately 1,070 as of Q3 2025[20] - Cash, cash equivalents, and short-term investments amounted to approximately $352.1 million as of September 30, 2025[29] ARCALYST Market and Usage - Approximately 20% of ARCALYST prescriptions are for patients on their first recurrence of pericarditis[16] - The majority of ARCALYST prescribing continues to come from the 14,000 multiple recurrence population[16] - Average total duration of ARCALYST therapy is approximately 32 months[20] - Payer approval rate for ARCALYST is greater than 90% of completed cases[20] Pipeline Development - KPL-387 received US Orphan Drug Designation for pericarditis, with Phase 2 data expected in the second half of 2026[10]